Please ensure Javascript is enabled for purposes of website accessibility

Why Pfizer, BioNTech, and Moderna Shot Higher Today

By Eric Volkman – Dec 30, 2021 at 6:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One coronavirus vaccine will apparently be authorized as a booster for younger people in the U.S.

What happened

Three of the top coronavirus stocks, Pfizer (PFE 0.43%), BioNTech (BNTX -3.21%), and Moderna (MRNA 0.84%), saw plenty of action on the market Thursday. Encouraging news for Pfizer and BioNTech's Comirnaty coronavirus vaccine pushed the share prices of those two companies slightly higher on the day, by a respective 1.4% and 6.7%, with fellow jab maker Moderna cruising along for the ride with a 1.5% gain.

So what

A report published Thursday morning in The New York Times stated that the Food and Drug Administration (FDA) plans to authorize booster shots of Pfizer and BioNTech's vaccine for people aged 12 to 15. Citing "people familiar with the agency's deliberations," the newspaper said the FDA also aims to authorize a booster for younger children (aged 5 to 11) burdened with immune deficiencies.

Gloved hand filling a syringe from a vial.

Image source: Getty Images.

If the article is accurate, it illustrates the regulator's wider goal to get more shots in arms generally -- hence the similar investor reaction with Moderna stock.

Comirnaty is an appropriate first choice for the new demographics, as it is so far the only coronavirus vaccine fully approved by the FDA, as opposed to having Emergency Use Authorization. Like Moderna's mRNA-1273, it has shown outstanding performance in late-stage clinical testing, and is a go-to jab throughout the U.S. and in other jurisdictions around the world.

Now what

No matter how the situation plays out with the omicron variant, the world will have to contend with the coronavirus for quite some time. We can fully expect pharmaceutical giant Pfizer to remain on the radar of a great many investors; the same can be said for the high-profile biotechs BioNTech and Moderna.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.